Supplementary Materials

Supplementary Material for:

Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer

Gaia Schiavon, Sarah Hrebien, Isaac Garcia-Murillas, Rosalind J. Cutts, Alex Pearson, Noelia Tarazona, Kerry Fenwick, Iwanka Kozarewa, Elena Lopez-Knowles, Ricardo Ribas, Ashutosh Nerurkar, Peter Osin, Sarat Chandarlapaty, Lesley-Ann Martin, Mitch Dowsett, Ian E. Smith, Nicholas C. Turner*

*Corresponding author. E-mail: nicholas.turner{at}

Published 11 November 2015, Sci. Transl. Med. 7, 313ra182 (2015)
DOI: 10.1126/scitranslmed.aac7551

This PDF file includes:

  • Fig. S1. ESR1 LBD digital PCR assays are sensitive and highly reproducible.
  • Fig. S2. Patients with ESR1 mutation have poor outcome on subsequent AI therapy.
  • Fig. S3. A theoretical model explains the evolution of ESR1 mutations during treatment for metastatic breast cancer.
  • Table S1. Clinical and pathological characteristics of the series of patients with advanced cancer.
  • Legend for table S2
  • Table S3. Ion AmpliSeq Breast Cancer driver and focal mutation gene panel.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S2. ESR1 mutations analyzed and experimental conditions (provided as an Excel file).